Abstract 12838: Efficacy of Antiarrhythmic Drug, Cibenzoline in Patients with Hypertrophic Obstructive Cardiomyopathy
Aim: It is reported that cibenzoline can decrease left ventricular pressure gradient in patients with hypertrophic obstructive cardiomyopathy (HOCM). We examined whether cibenzoline could decrease the incidence of cardiovascular complications in patients with HOCM.
Methods: One hundred and twenty-five patients with HOCM participated in this study. We have used cibenzoline as the drug for patients with HOCM since 1995. So, patients were divided into two groups. One group is 45 patients treated without cibenzoline (group A; mean age: 48±12 years) and the other group is 80 patients treated with cibenzoline (group B; 54±18 years). Cardiovascular complications and causes of death were checked. Mean follow-up periods were 206±86 months in group A and 142±70 months in group B.
Results: As to cardiovascular complications, group A had 32 patients with heart failure (HF) (71%), 24 with atrial fibrillation (AF) (53%), five with apoplexy (11%) and three with pacing therapy (7%). Group B had one patient with HF (1%, p<0.001 vs group A), five with AF (6%, p<0.001 vs group A) and two with pacing therapy (3%). As to death, in group A, 26 patients (58%) died. These 26 patients consisted of 20 HF death (77%), four sudden cardiac death (SCD) (15%) and two cancer (8%). In group B, six patients died (7.5%, p<0.001 vs group A). These six patients consisted of four SCD (67%), one suicide and one cancer.
Conclusion: These results indicate that the treatment with cibenzoline significantly decreased the cardiovascular complications and cardiac deaths in patients with HOCM. Thus, cibenzoline may be a promising therapy for patients with HOCM.
- © 2012 by American Heart Association, Inc.